medRxiv preprint doi: https://doi.org/10.1101/2023.10.17.23297061; this version posted October 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Transferability of a European-derived Alzheimer's Disease Genetic **Risk Score across Multi-Ancestry Populations.**

Aude Nicolas¹, Benjamin Grenier-Boley¹, Richard Sherva^{2,3}, Yoontae Kim⁴, Masataka Kikuchi⁵, Itziar de Rojas^{6,7}, Carolina Dalmasso^{8,9}, Xiaopu Zhou^{10,11,12}, Yann Le Guen^{13,14}, Carlos E Arboleda-Bustos¹⁵, Maria Aparecida Camargos Bicalho^{16,17,18}, Maëlenn Guerchet¹⁹, Sven van der Lee^{20,21}, Monica Goss²², Atahualpa Castillo²³, Céline Bellenguez¹, Fahri Küçükali^{24,25}, Claudia Satizabal Barrera^{22,26,27}, Bernard Fongang^{22,28,29}, Qiong yang^{26,27}, Oliver Peters^{30,31}, Anja Schneider^{32,33}, Martin Dichgans^{34,35,36}, Dan Rujescu³⁷, Norbert Scherbaum³⁸, Peters^{30,31}, Anja Schneider^{32,33}, Martin Dichgans^{34,35,36}, Dan Rujescu³⁷, Norbert Scherbaum³⁸, Jürgen Deckert³⁹, Steffi Riedel-Heller⁴⁰, Lucrezia Hausner⁴¹, Laura Molina Porcel^{42,43}, Emrah Düzel^{44,45}, Timo Grimmer⁴⁶, Jens Wiltfang^{47,48,49}, Stefanie Heilmann-Heimbach⁵⁰, Susanne Moebus⁵¹, Thomas Tegos⁵², Nikolaos Scarmeas^{53,54}, Oriol Dols-Icardo^{55,7}, Fermin Moreno^{56,7,57}, Jordi Pérez-Tur^{58,7}, María J. Bullido^{59,7,60,61}, Pau Pastor^{62,63}, Raquel Sánchez-Valle⁶⁴, Victoria Álvarez^{65,66}, Han Cao¹⁰, Nancy Y. Ip^{10,11,12}, Amy K. Y. Fu^{10,11,12}, Fanny C. F. Ip^{11,12}, Natividad Olivar⁶⁷, Carolina Muchnik⁶⁷, Carolina Cuesta⁶⁸, Lorenzo Campanelli⁶⁹, Patricia Solis⁷⁰, Daniel Gustavo Politis⁶⁸, Silvia Kochen⁷⁰, Luis Ignacio Brusco⁶⁷, Mercè Boada^{71,7}, Pablo García-González⁷¹, Raquel Puerta⁷¹, Pablo Mir^{72,7}, Luis M Real^{73,74,7}, Gerard Piñol-Ripoll^{75,76}, Jose María García-Alberca^{77,7}, Jose Luís Royo⁷⁸, Eloy Rodriguez-Rodriguez^{79,7}, Hilkka Soininen⁸⁰, Sami Heikkinen⁸¹, Alexandre de Mendonça⁸², Shima Mehrabian⁸³, Latchezar Traykov⁸⁴, Jakub Hort^{85,86}, Martin Vyhnalek^{85,86}, Katrine Laura Rasmussen^{87,88}, Jesper Qvist Thomassen⁸⁷, Yolande A.L. Pijnenburg²⁰, Henne Holstege^{20,89}, John van Swieten⁹⁰, Inez Ramakers⁹¹, Frans Verhey⁹¹, Aad van der Lugt⁹², Philip Scheltens²⁰, Jenny Ortega-Rojas¹⁵, Ana Gabriela Concha Mera¹⁵, Maria F. Mahecha¹⁵, Rodrogo Pardo¹⁵, Gonzalo Arboleda¹⁵, Caroline Graff⁹³, Goran Papenberg⁹⁴, Vilmantas Giedraitis⁹⁵, Anne Boland⁹⁶, Jean-François Deleuze⁹⁶, Luiz Armando de Marco^{97,17}, Edgar Giedraitis⁹⁵, Anne Boland⁹⁶, Jean-François Deleuze⁹⁶, Luiz Armando de Marco^{97,17}, Edgar Nunes de Moraes^{16,18}, Bernardo de Mattos Viana^{98,17,99}, Marco Túlio Gualberto Cintra^{16,18}, Anthony Grsiwold¹⁰⁰, Tatiana Forund¹⁰¹, Carlos Cruchaga^{102,103}, Jonathan Haines¹⁰⁴, Lindsay Farrer^{105,106,107,108,109}, Anita DeStefano¹¹⁰, Ellen Wijsman^{111,112,113}, Richard Mayeux^{114,115}, Margaret Pericak-Vance^{100,116}, Brian Kunkle¹⁰⁰, Alison Goate¹¹⁷, Gerard D. Schellenberg¹¹⁸, Badri Vardarajan^{114,115,119}, Li-San Wang¹¹⁸, Yuk Yee Leung¹¹⁸, Clifton Dalgard¹²⁰, Gael Nicolas¹²¹, David Wallon¹²¹, Carole Dufouil^{122,123}, Florence Pasquier¹²⁴, Olivier Hanon¹²⁵, Stéphanie Debette^{126,127}, Edna Grünblatt^{128,129,130}, Julius Popp^{131,132,133}, Bárbara Angel^{134,135}, Sergio Golger^{136,137}, Maria Victoria Chacon¹³⁶, Rafael Aranguiz^{136,138}, Paulina Orellana^{139,140}, Sergio Golger^{150,157}, Maria Victoria Chacon¹⁵⁰, Rafael Aranguiz^{150,150}, Paulina Orellana^{150,145}, Andrea Slachevsky^{139,141}, Christian Gonzalez-Billault¹³⁹, Cecilia Albala^{134,142}, Patricio Fuentes^{143,144}, Tenielle Porter^{145,146,147}, Simon M Laws^{145,146,147}, Perminder Sachdev¹⁴⁸, Karen Mather¹⁴⁸, Richard L. Hauger^{149,150}, Victoria Merritt^{151,152,153}, Matthew Panizzon^{152,154,153}, Rui Zhang², Michael Gaziano^{155,156}, Roberta Ghidoni¹⁵⁷, Daniela Galimberti^{158,159}, Beatrice Arosio¹⁶⁰, Patrizia Mecocci^{161,162}, Vincenzo Solfrizzi¹⁶³, Lucilla Parnetti¹⁶⁴, Alessio Squassina¹⁶⁵, Lucio Tremolizzo¹⁶⁶, Barbara Borroni^{167,168}, Benedetta Nacmias^{169,170}, Paolo Caffarra¹⁷¹, Davide Seripa¹⁷², Innocenzo Rainero¹⁷³, Antonio Daniele^{174,175}, Fabrizio Piras¹⁷⁶, Akinori Miyashita¹⁷⁷, Norikazu, Hara¹⁷⁷, Kouichi, Ozaki¹⁷⁸, Shumpoi, Niida¹⁷⁸, Julio Caffarra¹⁷¹, Davide Seripa¹⁷², Innocenzo Rainero¹⁷³, Antonio Daniele^{174,175}, Fabrizio Piras¹⁷⁶, Akinori Miyashita¹⁷⁷, Norikazu Hara¹⁷⁷, Kouichi Ozaki¹⁷⁸, Shumpei Niida¹⁷⁸, Julie Williams^{179,23}, Carlo Masullo¹⁸⁰, Philippe Amouyel¹⁸⁰, Pierre-Marie Preux¹⁹, Pascal Mbelesso^{19,181}, Bébène Bandzouzi¹⁸², Andy Saykin^{183,101}, Frank Jessen^{184,32,185}, Patrick Kehoe¹⁸⁶, Cornelia Van Duijn^{187,188}, Jungsoo Gim⁴, Nesrine Ben Salem¹⁸⁹, Ruth Frikke-Schmidt^{87,88}, Lofti Cherni^{189,190}, Michael D. Greicius¹³, Magda Tsolaki^{52,190}, Pascual Sánchez-Juan^{191,7}, Marco Aurélio Romano Silva^{98,17}, Kristel Sleegers^{24,25}, Martin Ingelsson^{192,193,194}, Jean-François Dartigues¹⁹⁵, Sudha Seshadri^{22,26,27}, Giacomina Rossi¹⁹⁶, Laura Morelli⁶⁹, Mikko Hiltunen⁸¹, Rebecca Sims²³, Wiesje van der Flier²⁰, Ole Andreassen^{197,198}, Humberto Arboleda¹⁵, Valentina Escott-Price^{199,179}, Agustín Ruiz^{200,7}, Kun Ho Lee⁴, Takeshi Ikeuchi¹⁷⁷, Alfredo Ramirez^{8,201,202,32}, Mark Logue^{203,204,205,206}, Jean-Charles Lambert¹

- Correspondence
- Jean-Charles.lambert@pasteur-lille.fr

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- ¹Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et déterminants
 moléculaires des maladies liées au vieillissement, Lille, France
- ²National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston, MA, USA
- ³Biomedical genetics/Department of Medicine, Boston University Chobanian & Avedisian School of Medicine,
 Boston, MA, USA
- ⁴BK FOUR Department of Integrative Biological Sciences, Chosun University, Gwangju, Republic of Korea
 ⁵University of Tokyo, Graduate School of Frontier Science, Japan
- ⁶Research Center and Memory Clinic, ACE Alzheimer Center Barcelona. Universitat Internacional de Catalunya,
 Spain
- ⁷CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of
 Health Carlos III, Madrid, Spain
- ⁸Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of
 Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
 ⁹Estudios en Neurociencias y Sistemas Complejos (ENyS) CONICET-HEC-UNAJ, Argentina
- ¹⁰Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The
 Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China
- ¹¹Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
- 72 ¹²Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST, China
- Shenzhen Research Institute, Shenzhen–Hong Kong Institute of Brain Science, Shenzhen, Guangdong 518057
 China
- ¹³Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA,
 USA
- 77 ¹⁴Institut du Cerveau Paris Brain Institute ICM, Paris, France
- ¹⁵Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de
 Colombia, Bogota, Colombia
- ¹⁶Department of Clinical Medicine, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Geraes,
 Brazil
- ¹⁷National Institute of Science and Technology (INCT) Neurotec R, Federal University of Minas Geraes, Belo
 Horizonte, Minas Geraes, Brazil
- ¹⁸Geriatrics Service of the University Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Geraes,
 Brazil
- ¹⁹Inserm U1094, IRD UMR270, Univ. Limoges, CHU Limoges, EpiMaCT Epidemiology of chronic diseases in
 tropical zone, Institute of Epidemiology and Tropical Neurology, Omega Health, Limoges, France
- ²⁰Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit
 Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
- ²¹Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam
 Neuroscience, Vrije University, Amsterdam, The Netherlands.
- 92 ²²Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA
- ²³Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Wales, UK
- 94 ²⁴Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- 95 ²⁵Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- 96 ²⁶Boston University and the NHLBI's Framingham Heart Study, Boston, MA, USA
- 97 ²⁷Department of Neurology, Boston University School of Medicine, Boston, MA, USA
- ²⁸Department of Biochemistry and Structural Biology, University of Texas Health Science Center, San Antonio,
 TX, USA
- 100 ²⁹Department of Population Health Sciences, University of Texas Health Science Center, San Antonio, TX, USA
- 101 ³⁰German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
- 102 ³¹Charité Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu
- 103 Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Berlin, Germany
- 104 ³²German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
- ³³Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-
- 106 Campus 1, 53127 Bonn, Germany
- 107 ³⁴Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
- 108 ³⁵German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- 109 ³⁶Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- 110 ³⁷Department of Psychiatry and Comprehensive Center of Neuroscience and Mental Health, Medical University of
- 111 Vienna, Vienna, Austria

perpetuity. It is made available under a CC-BY-NC 4.0 International license.

- ³⁸Department of Psychiatry and Psychotherapy, LVR-Klinikum Essen, University of Duisburg-Essen, Germany 112
- 113 Medical Faculty, Germany

114 ³⁹Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of 115 Würzburg, Germany

- ⁴⁰Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, 04103 Leipzig, 116 117 Germany.
- ⁴¹Department of Geriatric Psychiatry, Central Institute for Mental Health Mannheim, Faculty Mannheim, University 118 119 of Heidelberg, Germany
- ⁴²Neurological Tissue Bank Biobanc- Hospital Clinic -FRCB IDIBAPS, Barcelona, Spain 120
- 121 ⁴³Alzheimer's disease and other cognitive disorders Unit. Neurology Department, Hospital Clinic, Barcelona, 122 Spain
- 123 ⁴⁴German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
- ⁴⁵Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, 124 125 Germanv
- ⁴⁶Center for Cognitive Disorders, Department of Psychiatry and Psychotherapy, Technical University of Munich, 126 127 School of Medicine, Munich, Germany
- ⁴⁷Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany 128
- 129 ⁴⁸German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
- ⁴⁹Medical Science Department, iBiMED, Aveiro, Portugal 130
- ⁵⁰Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, 131 132 Germanv
- ⁵¹Institute for Urban Public Health, University Hospital Essen, University Duisburg-Essen, Germany 133
- 134 ⁵²1st Department of Neurology, Medical school, Aristotle University of Thessaloniki, Thessaloniki, Makedonia, 135 Greece
- ⁵³1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical 136 137 School, Greece
- ⁵⁴Depatment of Neurology, Columbia University, New York, NY, USA 138
- ⁵⁵Genetics of Neurodegenerative Diseases Unit IIB Sant Pau, Barcelona, Spain 139
- 140 ⁵⁶Department of Neurology. Hospital Universitario Donostia. San Sebastian, Spain
- ⁵⁷Neurosciences Area. Instituto Biogipuzkoa. San Sebastian, Spain 141
- 142 ⁵⁸Unitat de Genètica Molecular, Institut de Biomedicina de València-CSIC, Valencia, Spain
- ⁵⁹Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Spain 143
- ⁶⁰Instituto de Investigacion Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain 144
- 145 ⁶¹Universidad Autónoma de Madrid
- 146 ⁶²Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i Pujol, 147 Badalona, Barcelona, Spain
- ⁶³The Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain 148
- ⁶⁴Alzheimer's disease and other cognitive disorders unit. Service of Neurology. Hospital Clínic of Barcelona. 149
- 150 Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
- 151 ⁶⁵Laboratorio de Genética. Hospital Universitario Central de Asturias, Oviedo, Spain
- ⁶⁶Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain 152
- ⁶⁷Center of Neuropsychiatry and Behavior Neurology, School of Medicine, University of Buenos Aires, Argentina 153
- 154 ⁶⁸Hospital Interzonal General de Agudos-Eva Perón, Argentina
- ⁶⁹Laboratory of Brain Aging and Neurodegeneration. Fundacion Instituto Leloir-IIBBA, Argentina 155 ⁷⁰Studies in Neuroscience and Complex Systems Unit-CONICET-HEC-UNAJ, Argentina 156
- 157 ⁷¹Research Center and Memory clinic. ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, 158 Spain
- ⁷²Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología. Instituto de Biomedicina de 159 160 Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
- ⁷³Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen de Valme, Spain 161
- 162 ⁷⁴Depatamento de Bioquímica Médica, Biología Molecular e Inmunología. Facultad de Medicina. Universidad de 163 Sevilla. Sevilla, Spain
- ⁷⁵Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain 164
- ⁷⁶Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain 165
- ⁷⁷Alzheimer Research Center & Memory Clinic, Andalusian Institute for Neuroscience, Málaga, Spain. 166
- ⁷⁸Depatamento de Especialidades Quirúrgicas, Bioquímica e Inmunología. Facultad de Medicina. Universidad de 167
- 168 Málaga. Málaga, Spain

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 169 ⁷⁹Neurology Service, Margués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, 170 Spain. ⁸⁰Institute of Clinical Medicine - Neurology, University of Eastern Finland, Finland 171 ⁸¹Institute of Biomedicine, University of Eastern Finland, Finland 172 ⁸²Faculty of Medicine, University of Lisbon, Portugal 173 174 ⁸³Clinic of Neurology, UH "Alexandrovska", Medical University - Sofia, Sofia, Bulgaria ⁸⁴Department of Neurology, UH "Alexandrovska", Medical University, Sofia, Bulgaria 175 ⁸⁵Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University 176 177 Hospital, Czech Republic 178 ⁸⁶International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic ⁸⁷Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark 179 180 ⁸⁸Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark ⁸⁹Department of Clinical Genetics, VU University Medical Centre, Amsterdam, The Netherlands 181 ⁹⁰Department of Neurology, ErasmusMC, the Netherlands 182 ⁹¹Maastricht University, Department of Psychiatry & Neuropsychologie, Alzheimer Center Limburg, Maastricht, the 183 184 Netherlands ⁹²Department of Radiology&Nuclear medicine, ErasmusMC, the Netherlands 185 186 ⁹³Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital-Solna, 171 64 Stockholm Sweden 187 ⁹⁴Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and 188 Stockholm University, Stockholm, Sweden ⁹⁵Dept.of Public Health and Carins Sciences / Geriatrics, Uppsala University, Sweden 189 ⁹⁶Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), 91057, Evry, 190 191 France ⁹⁷Department of Surgery, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Geraes, Brazil 192 ⁹⁸Department of Psychiatry, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Geraes, Brazil 193 ⁹⁹Psychiatry Service of the University Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Geraes, 194 Brazil 195 196 ¹⁰⁰The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA 197 ¹⁰¹Department of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana, USA ¹⁰²Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA 198 199 ¹⁰³NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO 63110, USA ¹⁰⁴Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA 200 ¹⁰⁵Department of Biostatistics, Boston University, Boston, Massachusetts, USA 201 ¹⁰⁶Department of Epidemiology, Boston University, Boston, Massachusetts, USA 202 203 ¹⁰⁷Department of Medicine (Biomedical Genetics), Boston University, Boston, Massachusetts, USA ¹⁰⁸Department of Neurology, Boston University, Boston, Massachusetts, USA 204 ¹⁰⁹Department of Ophthalmology, Boston University, Boston, Massachusetts, USA 205 ¹¹⁰Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA 206 ¹¹¹Department of Genome Sciences, University of Washington, Seattle, Washington, USA 207 208 ¹¹²Department of Medicine (Medical Genetics), University of Washington, Seattle, Washington, USA 209 ¹¹³Department of Biostatistics, University of Washington, Seattle, Washington, USA ¹¹⁴Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, 210 211 New York, New York, USA ¹¹⁵Gertrude H. Sergievsky Center, Columbia University, New York, New York, USA 212 ¹¹⁶Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida, USA 213
- 214 ¹¹⁷Department of Neuroscience, Mount Sinai School of Medicine, New York, New York, USA
- ¹¹⁸Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of
 Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
- 217 ¹¹⁹Department of Neurology, Columbia University, New York, New York, USA
- 218 ¹²⁰Uniformed Services University of the Health Sciences; The American Genome Center, Bethesda, USA
- ¹²¹Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNR MAJ, F 76000 Rouen, France
- ¹²²Inserm, Bordeaux Population Health Research Center, UMR 1219, Univ. Bordeaux, ISPED, CIC 1401-EC, Univ
 Bordeaux, Bordeaux, France
- 223 ¹²³CHU de Bordeaux, Pole santé publique, Bordeaux, France
- 224 ¹²⁴Univ Lille Inserm 1171, CHU Clinical and Research Memory Research Centre (CMRR) of Distalz Lille France.
- 225 ¹²⁵Université de Paris, EA 4468, APHP, Hôpital Broca, Paris, France
- 226 ¹²⁶University Bordeaux, Inserm, Bordeaux Population Health Research Center, France

perpetuity. It is made available under a CC-BY-NC 4.0 International license.

- 227 ¹²⁷Department of Neurology, Bordeaux University Hospital, Bordeaux, France
- 228 ¹²⁸Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich,
- 229 University of Zurich, Zurich, Switzerland
- ¹²⁹Neuroscience Center Zurich, University of Zurich and ETH Zurich, Switzerland 230
- ¹³⁰Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland 231
- 232 ¹³¹Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland
- 233 ¹³²Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich, Zürich, Switzerland
- ¹³³Institute for Regenerative Medicine, University of Zürich, Switzerland 234
- ¹³⁴Public Health Nutrition Unit, Institute of Nutrition and Food Technology, University of Chile, Chile 235 236 ¹³⁵Interuniversity Center for Healthy Aging RED21993, Chile
- ¹³⁶Biomedica Research Group, Centro de Estudios Clínicos, Santiago, Chile 237
- 238 ¹³⁷Departamento de Psiquiatría y Salud Mental, Campus Oriente, Facultad de Medicina, Universidad de Chile, 239 Santiago, Chile
- 240
- ¹³⁸Instituto Nacional de Geriatría, Santiago, Chile
- ¹³⁹Geroscience Center for Brain Health and Metabolism, Santiago, Chile 241
- ¹⁴⁰Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibanez, Chile 242
- 243 ¹⁴¹Memory and Neuropsychiatric Center (CMYN) Neurology Department, Hospital del Salvador y Facultad de 244 Medicina, Universidad de Chile. Santiago, Chile
- 245 ¹⁴²Interuniversity Center for Healthy Aging RED21993, santiago, Chile
- ¹⁴³Geriatrics Section Clinical Hospital University of Chile, Chile 246
- ¹⁴⁴Neurology Service Hospital del Salvador, Santiago, Chile 247
- ¹⁴⁵Centre for Precision Health, Edith Cowan University, Joondalup, Perth, Australia 248
- 249 ¹⁴⁶Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan 250 University, Joondalup, Perth, Australia
- ¹⁴⁷Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Australia 251
- ¹⁴⁸Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, 252 253 Sydney, Australia
- ¹⁴⁹Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare System, San Diego, 254 255 CA, USA
- ¹⁵⁰Center for Behavior Genetics of Aging, University of California San Diego, La Jolla, CA, USA 256
- 257 ¹⁵¹VA San Diego Healthcare System, San Diego, CA, USA; Department of Psychiatry 258 ¹⁵²Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
- ¹⁵³Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, CA, USA 259
- ¹⁵⁴Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla, CA, USA 260
- 261 ¹⁵⁵5Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare 262 System, Boston, MA, USA
- ¹⁵⁶Division of Aging, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA 263
- ¹⁵⁷Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy 264
- ¹⁵⁸Neurodegenerative Diseases Unit, Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan, Italy 265
- ¹⁵⁹Dept. of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy 266
- ¹⁶⁰Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy 267
- ¹⁶¹Institute of Gerontology and Geriatrics, Department of Medicine and Surgery, University of Perugia, Italy 268
- 269 ¹⁶²Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, 270 Stockholm, Sweden
- ¹⁶³Interdisciplinary Department of Medicine, Geriatric Medicine and Memory Unit, University of Bari "A. Moro, Bari, 271 272 Italy
- ¹⁶⁴Centre for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, University of Perugia, 273 274 Italy
- ¹⁶⁵Department of Biomedical Sciences, University of Cagliari, Italy. 275
- ¹⁶⁶Neurology, IRCCS San Gerardo dei Tintori, Monza and University of Milano-Bicocca, Italy 276
- 277 ¹⁶⁷Deaprtment of Clinical and Experimental Sciences, University of Brescia Italy
- 278 ¹⁶⁸Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia, Brescia, Italy
- 279 ¹⁶⁹Department of Neuroscience, Psychology, Drug Research and Child Health University of Florence, Italy
- ¹⁷⁰IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy 280
- ¹⁷¹Past Director Dementia Unit University of Parma, Parma, Italy 281
- ¹⁷²Department of Hematology and Stem Cell Transplant, Vito Fazzi Hospital, Lecce, Italy 282
- ¹⁷³Department of Neuroscience "Rita Levi Montalcini", University of Torino, Torino, Italy 283
- ¹⁷⁴Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy. 284

perpetuity. It is made available under a CC-BY-NC 4.0 International license.

- 285 ¹⁷⁵Neurology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.
- ¹⁷⁶Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy 286
- ¹⁷⁷Niigata University, Brain Research Institute, Japan 287
- ¹⁷⁸Research Center, National Center for Geriatrics and Gerontology, Japan 288
- ¹⁷⁹UK Dementia Research Institute, Cardiff University, UK 289
- 290 ¹⁸⁰Institute of Neurology, Catholic University of the Sacred Heart, Rome, Itlay
- 291 ¹⁸¹Department of Neurology, Amitié Hospital, Bangui, Central African Republic
- ¹⁸²Department of Neurology, Brazzaville University Hospital, Brazzaville, Republic of Congo 292
- ¹⁸³Department of Radiology, Indiana University, Indianapolis, Indiana, USA 293
- 294 ¹⁸⁴Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University 295 of Cologne, Cologne, Germany
- 296 ¹⁸⁵Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), University of 297 Cologne, Cologne, Germany
- ¹⁸⁶Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK 298
- ¹⁸⁷Department of Epidemiology, ErasmusMC, Rotterdam, The Netherlands 299
- ¹⁸⁸Nuffield Department of Population Health Oxford University, Oxford, UK 300
- ¹⁸⁹High Institute of Biotechnology, University of Monastir, Monastir, Tunisia. 301
- 302 ¹⁹⁰Laboratory of Genetics, Immunology and Human Pathology, Faculty of Science of Tunis, University of Tunis El 303 Manar, 2092 Tunis, Tunisia.
- ¹⁹¹Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, 28031 Madrid, Spain. 304
- ¹⁹²Dept. of Public Health and Caring Sciences / Geriatrics, Uppsala University, Uppsala, Sweden 305
- ¹⁹³Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada 306
- 307 ¹⁹⁴Tanz Centre for Research in Neurodegenerative Diseases, Departments of Medicine and Laboratory Medicine
- & Pathobiology, University of Toronto, Toronto, Ontario, Canada 308
- ¹⁹⁵Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France 309
- ¹⁹⁶Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy 310
- ¹⁹⁷NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway 311
- ¹⁹⁸Institute of Clinical Medicine, University of Oslo, Oslo, Norway 312
- 313 ¹⁹⁹Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, UK
- ²⁰⁰Research Center and Memory clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat 314 315
- Internacional de Catalunya, Barcelona, Spain
- 316 ²⁰¹Department of Neurodegenerative diseases and Geriatric Psychiatry, University Hospital Bonn, Medical 317 Faculty, Bonn, Germany
- 318 ²⁰²Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San 319 Antonio, TX, USA
- ²⁰³National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston MA 320
- ²⁰⁴Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, Boston MA 321
- ²⁰⁵Biomedical genetics/Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, 322 323 Boston MA.
- 324 ²⁰⁶Department of Biostatistics, Boston University School of Public Health, Boston, MA.

medRxiv preprint doi: https://doi.org/10.1101/2023.10.17.23297061; this version posted October 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

We built a genetic risk score (GRS) from the most complete landscape of the 325 326 Alzheimer disease (AD) genetics. We extended its analysis in 16 European countries and observed a consistent association of this GRS with AD risk, age at onset and 327 cerebrospinal fluid (CSF) AD biomarker levels regardless of the Apolipoprotein E 328 329 (APOE) genotype. This GRS was also associated with AD risk (independently of APOE) with a decreasing order of magnitude in those with an European-American, 330 North-African, East-Asian, Latin-American, African-American background respectively. 331 332 No association of the GRS to AD was seen in sub-Saharan African and Indian populations. This GRS captures information specific to AD as its association 333 334 decreases as the diagnosis broadens. In conclusion, a simple GRS captures shared genetic information specific to AD between multi-ancestry populations. However, 335 more population diversity is needed to better understand the AD genetic complexity 336 337 across populations.

338

Over the past 15 years, genome-wide association studies (GWAS) have successfully 339 340 identifying the genetic component of multifactorial diseases. This has led to the development of several powerful approaches that help decipher pathophysiological processes and 341 propose potential diagnostic/prognostic tools. These tools include GRS, a cumulative effect 342 score summarizing the information distributed across individual susceptibility genome-wide 343 significant variants or polygenic risk scores (PRS, an extension of GRS to loci of small effect, 344 without genome-wide significant associations to potentially capture additional predictive 345 capacity¹. 346

Due to high estimate of the genetic component of AD, i.e., heritability of 60-80% in twin 347 348 studies², such GRSs/PRSs have logically been of particular interest in this pathology. Many GRS/PRS have therefore been developed to assess their associations with AD and related 349 disease (ADRD) risk or with ADRD-related endophenotypes such as age at onset³, brain 350 imaging⁴⁻⁶ or CSF biomarkers^{7,8}. In almost of these studies, the GRSs/PRSs were 351 significantly associated with the quantitative or binary traits of interest. However, 352 353 comparisons between publications, even for the same trait such as AD risk, appear to be difficult due to obvious differences in the populations analyzed, heterogeneity in summary 354 statistics and in the variants included, or different statistical methods used to calculate the 355 PRSs⁹. In addition, most of the GRSs/PRSs approaches have been developed utilizing 356 European ancestry populations, and only a few studies have investigated the relevance of 357 such tools in different ancestries^{10,11}. 358

Recently, a GRS built from the most complete and reliable landscape of AD genetics, 359 including 75 AD risk loci (and 83 independent signals excluding APOE) generated by the 360 European Alzheimer & Dementia Biobank (EADB) consortium, was tested in a limited 361 number of European ancestry cohorts¹². This GRS was found to be associated with the risk 362 363 of developing future AD/dementia in population-based studies, or of progressing from mild 364 cognitive impairment to AD/dementia. In this context, we decided to validate the association 365 of this GRS with AD risk, CSF biomarker levels and age at onset in populations from 16 366 European countries. We also decided to extend the study of this GRS to include different ancestries from Asia. Africa and Latin America. 367

The different populations analyzed in this work are described in Supplementary Table 1. Two 368 main GRSs were calculated (see Supplementary Table 1 for the different adjustments used 369 per population and Supplementary Table 2 for the list of SNPs used); (i) a GRS including the 370 371 genome-wide significant and independent sentinel SNPs at the loci reported by Bellenguez 372 et al. (referred to as GRS^{ALZ}) and (ii) a GRS including these sentinel SNPs and adjusted for the number of APOE- ϵ 2 and APOE- ϵ 4 alleles (GRS^{ALZadjAPOE}). 373

374 We first analyzed the association of these GRSs with the risk of developing AD in casecontrol studies from 16 countries representative of the European genetic diversity of the 375 EADB. All the GRS distributions in cases and controls are shown in Supplementary Figures 376 1-3. All countries were analyzed independently and the Odd Ratios (ORs) indicate the effect 377 378 of the GRS as the increase in the risk of AD associated with each additional allele of average risk in the GRS. GRS^{ALZ} appeared to be significantly associated with AD in a homogeneous 379

manner across Europe. The association of GRS^{ALZ} with AD risk was little affected when the impact of $\epsilon 2/\epsilon 3/\epsilon 4$ APOE alleles ($GRS^{ALZadjAPOE}$) was considered (Fig. 1). Of note, $GRS^{ALZadjAPOE}$ was also associated with a younger age at onset (Supplementary Fig. 4).

We then generated a mega-analysis based on the EADB datasets of the 16 European 383 countries in order to assess in the most precise way, the risk of developing AD according to 384 GRS strata, i.e. 0-2%, 2-5%, 10-20%, 20-40%, 60-80%, 80-90%, 90-95%, 95-98% and finally 385 98-100%. The 40-60% GRS stratum was used as the reference. In this analysis, we also 386 generated a GRS including the sentinel SNPs of the GWAS loci but also the two SNPs 387 defining the $\epsilon 2/\epsilon 3/\epsilon 4$ APOE alleles (GRS^{ALZinclAPOE}). Results are shown in Fig 2A and as 388 expected the risk of developing AD in the most extreme strata is particularly high when 389 APOE is included in the GRS. However, association of GRS^{ALZ} was also significant in all the 390 strata analyzed and not impacted when adjusted for the number of APOE-2 and APOE-24 391 alleles (GRS^{ALZajAPOE}). In the two extreme 0-2% and 98-100% strata, both GRS^{ALZ} and 392 GRS^{ALZadjAPOE} were associated with a decrease of more than 2-fold or an increase of more 393 394 than 3-fold of the AD risk when compared with the 40-60% stratum (see Fig. 2A and Supplementary Table 3). 395

Since all the analyses suggested an association of GRS^{ALZ} independently of the APOE 396 status, we took advantage of our large mega-analysis to fully address how GRS^{ALZ} interacts 397 with the APOE genotypes. For this purpose, we stratified in 4 groups the mega-analysis 398 according to the APOE genotype by grouping together the $\varepsilon 2\varepsilon 2/\varepsilon 2\varepsilon 3$, $\varepsilon 3\varepsilon 3$, $\varepsilon 2\varepsilon 4/\varepsilon 3\varepsilon 4$, $\varepsilon 4\varepsilon 4$ 399 carriers. We then assessed in each of these subpopulations, the association of GRS^{ALZ} with 400 401 AD risk per guintile strata (0-20%, 20-40%, 60-80% and 80-100%) with the 40-60% stratum as a reference. Remarkably, GRS^{ALZ} appeared to be homogenously associated with AD risk 402 in all the strata indicating that the APOE and GRS^{ALZ} risk are independent (Fig. 2B and 403 Supplementary Table 4). 404

To determine whether these GRSs are associated with pathophysiological processes known 405 to be involved in the AD pathology, we used a large GWAS on CSF Aβ42, Tau and p-Tau 406 that we generated through EADB, including 5,944 individuals¹³. GRS^{ALZ} was associated with 407 408 a decrease in A_β42 levels and with an increase in Tau and pTau levels that fits with the increased AD risk associated with this GRS (Fig. 3). GRS^{ALZadjAPOE} was similarly significantly 409 associated with these endophenotype levels (Fig. 3). It should be noted that although the 410 association of these GRSs with the level of A β 42 in CSF appears to be highly heterogeneous 411 between populations, their associations with the levels of Tau and p-Tau are, on the contrary, 412 highly homogeneous in the same populations. This could be interpreted as Tau and p-Tau 413 concentrations directly reflecting pathophysiological processes (probably neuronal) that 414 depend on the genetic factors of Alzheimer's disease. CSF A β 42 concentrations, on the 415 other hand, would depend on multiple intermediate processes, leading to the heterogeneity 416 417 observed between the different populations.

Following the assessment of these GRS associations with AD risk and endophenotypes in 418 European populations, we thought to extend their analyses to other European-ancestry 419 populations (USA) but to include also populations from India, East-Asia (China, Japan and 420 Korea), North-Africa (Tunisia), sub-Saharan Africa (Central African Republic/the Congo 421 422 Republic), South-America (Argentina, Brazil, Chile, and Colombia) as well as African-, 423 Native- and Latino-American admixture populations from US studies (more than 75% African- or Native-American ancestry or self-reporting for Latino-American populations) (Fig. 424 4). With the exception of Korea, where 71 SNPs were available, most GRSs were 425 constructed from 79-85 SNPs including APOE variants, supplementary Table 2). All the GRS 426 distributions in cases and controls are shown in Supplementary Figure 5-7. Of note, the 427 association of APOE with AD risk was heterogonous between these different populations as 428 previously described in several prior studies (Figure 4 and Supplementary Table 5)^{14,15}. 429

As expected, the AD risk associated with GRS^{ALZ} or GRS^{ALZadjAPOE} was highly similar between European and other European-ancestry populations (USA). Both GRSs were significantly associated with AD risk with a decreasing order of magnitude from Maghreb, East-Asian countries, Latino-American to African-American population admixture (Fig. 5 and

Supplementary Table 6). However, these GRSs had no association with risk of AD in the 434 435 sub-Saharan African and Indian populations. This may be related to the small sample size, which resulted in the study lacking statistical power. However, in African-American 436 admixture, the magnitude of association decreased as the African ancestry percentage 437 increases, to finally reach a level similar to that observed in our sub-Saharan African 438 population: association of GRS^{ALZadjAPOE} with AD risk populations with more than 90% African 439 ancestry is OR=1.02 (95% CI 1.00-1.05, P=9x10⁻²). This observation supports the 440 441 expectation that GRSs constructed on genetic data generated from European ancestry populations perform poorly in African ancestry populations. Similarly, in ADSP Native-442 American admixture, the magnitude of association decreased as the Native-American 443 ancestry percentage increases (from OR=1.05 95% CI 1.03-1.07, P=4.1x10⁻⁶, OR=1.04 95% 444 CI 1.02-1.06, P=9.0x10⁻⁴ to OR=1.03 95% CI 1.01-1.06, P=5.0x10⁻³, respectively in the 445 populations with more than 50%, 75% and 90% Native-American ancestry). Notably, a 446 similar finding was seen in Chilean and Argentinian populations v GRS^{ALZ} association diminishes when the Native American ancestry rises¹⁶. was seen in Chilean and Argentinian populations where the 447 448 Of note, GRS^{ALZadjAPOE} was also associated with a younger age at onset in most of the populations 449 studied (at least 100 AD cases) at the notable exception of the Chinese and Korean 450 populations Supplementary Fig. 8). Of note, the APOE $\varepsilon 2/\varepsilon 3/\varepsilon/4$ alleles strongly influence 451 age at onset in these two populations (Supplementary Fig. 9). 452

To refine our analysis in multi-ancestry populations, we calculated the association of GRS^{ALZadjAPOE} and GRS^{ALZinclAPOE} with AD risk per quintile strata (0-20%, 20-40%, 60-80% and 453 454 455 80-100%) with the 40-60% stratum as a reference in all our populations. Of note, Salsa, 456 Indian, North-Africa and sub-Saharan Africa populations were excluded because of their small sample size. Results were then meta-analyzed in order to increase statistical power. 457 Consistent with the results shown in Figure 5, the GRS^{ALZadjAPOE} association is very similar 458 between the European-ancestry and East-Asian populations, but less marked with the 459 Latino-American populations and the African-American admixture populations (Fig. 6 and 460 461 supplementary Table 7).

Finally, we took advantage of the Million Veteran Project (MVP) to assess how the association of GRS^{ALZadjAPOE} with the risk of AD behaved in multi-ancestry populations according to the diagnosis of dementia, that is, to see how a GRS derived from case/control studies using a specific diagnosis of AD performed when the diagnosis was broadened to dementia. GRS^{ALZadjAPOE} showed a decreasing association with AD risk as the diagnosis became less specific, irrespective of the multi-ancestry populations studied (Table 1).

468

By studying a large multi-ancestry diversity, our work highlights the importance of cross-469 470 ancestry studies in unravelling the genetic complexities of this devastating disease and contributes significantly to the understanding of AD risk assessment in diverse populations. 471 The vast majority of GWAS data available worldwide have been developed in European-472 ancestry populations and the study of the genetics of AD is no exception, especially as the 473 474 diagnosis of the disease is most often based on specialized clinical structures. This makes studying this disease more difficult in low- and middle-income countries. This is beginning to 475 476 change as new case-control studies are developed worldwide. However, it is difficult to compare the results obtained in European-ancestry GWASs since GWAS studies in these 477 non-European populations are currently of a size that is at best comparable to that of 478 European studies in the early 2010s^{17,18}. These studies are therefore underpowered to detect 479 at a genome-wide significant level most of the loci found in European populations. In 480 addition, the small size of some of these populations means that there is a risk of generating 481 false positives, as in silico replication is difficult given the sparsity of samples from that 482 483 population.

To address some of these limitations, we have chosen to develop a simple approach to better compare AD genetics across many populations worldwide. We used a GRS combining sentinel SNPs associated with the risk of developing AD in populations of European origin, as described previously¹². We tested its association with the risk of developing AD in the largest panel of diverse populations studied to date. We were able to observe a systematic

association of this GRS with all the populations under study, with the exception of Indian and
African Sub-Saharan populations, probably partly due to lack of statistical power. Our results
thus suggest that all multi-ancestry populations are likely to be affected by shared
pathophysiological processes driven in part by these genetic risk factors.

493 However, this study also reveals important differences between populations, especially in 494 African-ancestry populations: ORs are lowest for populations from African countries or of African-American admixture, with the ORs in African-American population, when their % 495 496 African ancestry reaches 90%, being similar to those measured in populations from sub-Saharan African countries. Our work thus suggests that the AD genetic architecture in 497 498 African-ancestry populations strongly differs from European-ancestry populations. Higher genetic diversity is observed in African-ancestry populations compared to non-African-499 ancestry populations¹⁹⁻²¹ and this likely implicates different causal variants in already known 500 loci (as previously described for ABCA7²² and/or different genes involved in the AD 501 pathophysiology as previously proposed in^{23,24}). 502

Such Genetic diversity likely explains part of the potential methodological reason for these 503 variations of the GRSALZ association across populations. First, although we attempted to 504 develop a comparable GRS, some SNPs were not present in all the populations studied or 505 506 were poorly imputed, with the likely consequence of underestimating the association of GRSs with AD risk in these populations. However, as these points mainly affect low-507 508 frequency variants (see Supplementary Table 2), their impacts on GRSs are likely to be limited. It should be noted that, limiting this imputation problem, some of the genetic data 509 were generated from whole genome sequencing (Alzheimer disease sequencing project 510 (ADSP) and China). Second, we used sentinel variants defined by populations of European 511 ancestry. Most of these are unlikely to be the causal variants and therefore, they do not 512 capture properly the association of a locus with the risk of developing AD in other ancestries 513 514 as the linkage disequilibrium structure of the genome changes across ancestries. This has already been described for a number of other diseases and populations. The implementation 515 of a PRS calculated based on well-powered GWAS data generated in the target population 516 might solve this problem^{25,26}. However, such an approach will require access to raw GWAS 517 data from different populations to generate accurate multi-ancestry PRSs as for instance 518 already generated in kidney diseases²⁷. Finally, it has been estimated that around 10-20% of 519 520 AD dementia is misdiagnosed, and we have observed that the more inaccurate the clinical diagnosis of AD dementia, the smaller the magnitude of the association in the GRS. This 521 522 observation suggests that our current GRSs capture information specific to AD, but that the quality of the clinical diagnose may interfere with measuring the association of this GRS with 523 the AD risk in a given population. This last point will have to be better controlled in the future 524 525 with the introduction of standardized diagnosis between different populations, for example, 526 based on biological markers (although there is also a need for more diversity in this field to 527 define the relevance of biomarkers in multi-ancestry populations).

Finally, our study also confirms the strong heterogeneity in the APOE $\varepsilon 2/\varepsilon 3/\varepsilon 4$ associations 528 529 with AD risk in different populations (Figure 4). Differential regulation of APOE expression related to different ancestral genomic background around the locus have been proposed to 530 account for the differences in risk between populations of various ancestries²⁸⁻³¹. In addition, 531 it has also been postulated that interaction with other genetic risk factors for AD may be an 532 explanation for this heterogeneity. However, our data also clearly indicate that GRSALZ 533 appears to be associated with AD risk regardless of APOE status whatever the population 534 studied. This observation suggests that we may have two independent genetic entities for 535 sporadic AD which fits remarkably well with the recent hypothesis of three variants of AD 536 (autosomal dominant AD, APOE ɛ4-associated sporadic AD and APOE ɛ4-unassociated 537 sporadic AD) that may lead to a possible revision of the current clinical taxonomy of AD³². 538

539 In conclusion, our various observations are a call for more genetic diversity in the study of 540 Alzheimer's disease. Although a simple GRS based on the largest European-ancestry GWAS 541 can capture relevant genetic information in most studied populations worldwide, there 542 appears to be important genetic heterogeneity between these populations. Characterizing 543 the global genetic architecture of AD in multi-ancestry populations (particularly African-

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

ancestry) may have important implications for understanding the pathophysiology of AD and 544 545 accelerating the development of strategies to prevent and treat AD.

546 547 **Acknowledgments**

548 We thank the many study participants, researchers, and staff for collecting and contributing 549 to the data and the high-performance computing service at the University of Lille. This work was funded by a grant (European Alzheimer&Dementia DNA BioBank, EADB) from the EU 550 551 Joint Programme – Neurodegenerative Disease Research (JPND) and the Fondation Recherche Alzheimer. A.N. was supported by Fondation pour la recherche médicale 552 553 (EQU202003010147). UMR1167 is also funded by the Inserm, Institut Pasteur de Lille, Lille Métropole Communauté Urbaine, and the French government's LABEX DISTALZ program 554 555 (development of innovative strategies for a transdisciplinary approach to Alzheimer's 556 disease). Full consortium acknowledgements and funding are in the Supplementary Note.

557

580

558 Author contributions

Project coordination: A.N., J-C.L; data collection coordination: A.N., Y.LG., J.G., M.D.G., 559 E.N.D.M., J-F.D., H.A., V.E-P., A.Rui., K.H.L., T.I., A.Ram., M.L., J-C.L; Data analyses: A.N, 560 B.G-B., R.S., Y.K., M.K., I.D.R., C.D., X.Z., Y.L.G. C.E.A-B., M.A.C.B., M.Gue., S.v.d.L., 561 M.Gos., A.C., C.B., F.K; EADB Sample contribution: I.d.R., A.C., S.V.D.L,, C.B., F.K., 562 O.P., A.Sch., M.D., D.R., N.Sch., D.J., S.R-H., L.H., L.M.P., E.D., O.G., J.Wilt., S.H-H., 563 S.Moe., T.T., N.Sca., J.C., F.M., J.P-T., M.J.B., P.P., R.S-V., V.Á. M.B., P.G-G., R.Pue., 564 P.Mir., L.M.R., G.P-R., J.M.G-A., J.L.R., E.R-R., H.S., T.K., A.d.M., S.Meh., J.Hor., M.V., 565 K.L.R., J.Q.T., Y.A.P., H.H. J.v.S., I.Ram., F.V., A.v.d.L. P.Sch., C.G., G.P., V.G., G.N., 566 567 C.Duf., F.P., O.H., S.D., A.B., J-F.Del., E.G., J.P., D.G., B.Aro., P.Mec., V.S., L.P., A.Squ, L.T., B.Bor., B.N., P.C., D.S., I.Rai., A.Dan., J.Will., C.Mas., P.A., F.J., P.K., C.V.D., R.F-S., 568 T.M., P.S-J., K.S., M.I., G.R., M.H., R.Sim., W.v.d.F., O.A., A.Rui., A.Ram., J-C.L., MVP 569 Sample contribution: R.She., R.H., V.M., M.P., R.Z., M.Gaz., M.L.; Salsa Sample 570 contribution: M.Gos., C.S.B., B.F., Q.Y. S.S.; ADSP Sample contribution: A.Gri., T.F., 571 572 C.Cru., J.Hai., L.F., A.Des., E.W., R.M., M.P-V., B.K., A.Goa., G.D.S., B.V., L-S.W., Y.Y.L., C.Dalg., A.Say., S.S.; Africa sample contribution: M.Gue., P-M.P., P.Mbe, B.Ban, J-573 F.Dar.; East-Asia sample contribution: Y.K., M.K., X.Z., H.C., N.Y.I., A.K.Y.F., F.C.F.I., 574 A.M., N.H., K.O., S.N., J.G., V.E-P., K.H.L., T.I.; South America sample contribution: 575 C.Dalm., C.E.A-B., M.A.C.B., N.O., C.Muc., C.Cue., L.Cam., P.Sol., D.G.P., S.K., L.I.B., J.O-576 577 R., A.G.C.M., M.F.M., R.Par., G.A., L.A.d.M., M.A.R.S., B.d.M.V., M.T.G.C., B.Ang., S.G., 578 M.V.C., R.A., P.O., A.Sla., C.G-B., C.A., P.F., E.N.d.M., L.M., H.A., A.Rui, A.Ram; Core 579 writing group: A.N, B.G-B., J-C.L.

581 **Competing Interests Statement**

C.C. has received research support from: GSK and EISAI. The funders of the study had no 582 583 role in the collection, analysis, or interpretation of data; in the writing of the report; or in the 584 decision to submit the paper for publication. CC is a member of the advisory board of Vivid 585 Genomics and Circular Genomics and owns stocks. L.M.P. received personal fees from 586 Biogen for consulting activities unrelated to the submitted work T.G. received consulting fees 587 from AbbVie, Alector, Anavex, Biogen, Cogthera, Eli Lilly, Functional Neuromodulation, Grifols, Igvia, Janssen, Noselab, Novo Nordisk, NuiCare, Orphanzyme, Roche Diagnostics, 588 Roche Pharma, UCB, and Vivoryon; lecture fees from Biogen, Eisai, Grifols, Medical 589 Tribune, Novo Nordisk, Roche Pharma, Schwabe, and Synlab; and has received grants to 590 591 his institution from Biogen, Eisai, and Roche Diagnostics.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

592 **References**

593 1. Osterman, M.D. et al, Polygenic Risk Scores. Curr. Protoc. 1, e126 (2021) 594 2. Gatz, M. et al,. Role of genes and environments for explaining Alzheimer disease. 595 596 Arch. Gen. Psychiatry 63, 168-74 (2006) 3. Desikan, R.S. et al, Genetic assessment of age-associated Alzheimer disease risk: 597 Development and validation of a polygenic hazard score. PLoS Med. 14, e1002258 598 599 (2017)4. Sabuncu, M.R et al, The association between a polygenic Alzheimer score and 600 601 cortical thickness in clinically normal subjects. Cereb. Cortex 22, 2653-61 (2012) 5. Mormino, E.C. et al, Polygenic risk of Alzheimer disease is associated with early- and 602 603 late-life processes. Neurology 87, 481-8 (2016) 6. Xicota, L. et al, Association of APOE-Independent Alzheimer Disease Polygenic Risk 604 605 Score With Brain Amyloid Deposition in Asymptomatic Older Adults. *Neurology* 99, 606 e462-75 (2022) 607 7. Sleegers, K. et al, A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42. 608 609 Alzheimers Dement. **11**, 1452-1460 (2015) 8. Hong, S. et al, Genome-wide association study of Alzheimer's disease CSF 610 biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. Transl. 611 Psychiatry. 10, 403 (2020) 612 9. Clark, K. et al, Polygenic Risk Scores in Alzheimer's Disease Genetics: Methodology, 613 Applications, Inclusion, and Diversity. J. Alzheimers Dis. 89, 1-12 (2022) 614 10. Sariya, S. et al, Polygenic Risk Score for Alzheimer's Disease in Caribbean 615 Hispanics. Ann. Neurol. 90 366-376 (2021) 616 617 11. Jung, S.H. et al, Transferability of Alzheimer Disease Polygenic Risk Score Across Populations and Its Association With Alzheimer Disease-Related Phenotypes. JAMA 618 Netw. Open. 5, e2247162 (2022) 619 620 12. Bellenguez, C. et al, New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat. Genet. 54, 412-436 (2022) 621 13. Jansen, I.E. et al, Genome-wide meta-analysis for Alzheimer's disease cerebrospinal 622 fluid biomarkers. Acta Neuropathol. 144, 821-842 (2022) 623 14. Logue, M.W. Et al. Genetics of Alzheimer's Disease in the African American 624 625 Population. J. Clin. Med. 12, 5189 (2023) 15. Miyashita, A. et al, Genetics of Alzheimer's disease: an East Asian perspective. J 626 Hum. Genet. 68, 115-124 (2023) 627 16. Dalmasso MC, et al, First GWAS on Alzheimer's Disease in Argentina and Chile 628 populations. medRxiv, doi.10.1101/2023.01.16.23284609 629 17. Hollingworth, P; et al, Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 630 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 43, 429-435 (2011) 631 18. Naj, A.C. et al, Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are 632 associated with late-onset Alzheimer's disease. Nat. Genet 43,436-41 (2011) 633 19. Campbell, M.C. Et al. African genetic diversity: implications for human demographic 634 history, modern human origins, and complex disease mapping. Annu. Rev. Genomics 635 Hum. Genet. 9, 403-33 (2008) 636 20. Taliun, D. et al, Sequencing of 53,831 diverse genomes from the NHLBI TOPMed 637 638 Program. Nature 590, 290-299 (2021) 21. Byrska-Bishop, M. et al, High-coverage whole-genome sequencing of the expanded 639 1000 Genomes Project cohort including 602 trios. Cell 185, 3426-3440 (2022) 640 641 22. Reitz, C. et al, Alzheimer Disease Genetics Consortium. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ 4,and the risk of late-onset 642 Alzheimer disease in African Americans. JAMA 309, 1483-92 (2013) 643 23. Kunkle, B.W. et al, Novel Alzheimer Disease Risk Loci and Pathways in African 644 645 American Individuals Using the African Genome Resources Panel: A Meta-analysis. 646 JAMA Neurol. 78, 102-113 (2021)

medRxiv preprint doi: https://doi.org/10.1101/2023.10.17.23297061; this version posted October 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

- 24. Sherva, R. et al, African ancestry GWAS of dementia in a large military cohort 647 identifies significant risk loci. Mol. Psychiatry 28, 1293-1302 (2023) 648
- 25. Choi, SW. et al, Tutorial: a guide to performing polygenic risk score analyses. Nat. 649 Protoc. 15, 2759-2772 (2020) 650
- 26. Wand, H. et al, Improving reporting standards for polygenic scores in risk prediction 651 studies. Nature 591, 211-219 (2021) 652
- 27. Khan, A. et al, Genome-wide polygenic score to predict chronic kidney disease 653 across ancestries. Nat. Med. 28, 1412-1420 (2022) 654
- 28. Rajabli, F. et al, Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican 655 656 and African American populations. PLoS Genet. 14, e1007791 (2018)
- 29. Bussies, P.L., et al, Use of local genetic ancestry to assess TOMM40-523' and risk 657 for Alzheimer disease. Neurol. Genet. 6, e404 (2020) 658
 - 30. Nuytemans, K. et al, Identifying differential regulatory control of APOE £4 on African versus European haplotypes as potential therapeutic targets. Alzheimers Dement. 18, 1930-1942 (2022)
 - 31. Rajabli, F. et al, A locus at 19q13.31 significantly reduces the ApoE ɛ4 risk for Alzheimer's Disease in African Ancestry. PLoS Genet. 18, e1009977 (2022)
- 664 32. Frisoni, GB. et al, The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. Nat. Rev. Neurosci. 23, 53-66 (2022) 665

666

659

660

661

662

663

medRxiv preprint doi: https://doi.org/10.1101/2023.10.17.23297061; this version posted October 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

METHODS Online 667

668

GRS computation 669

GRS^{ALZ} includes the 83 independent signals associated with AD. GRS^{ALZinclAPOE} have two 670 additional SNPs to the list of 83: rs7412, rs429358, encoding APOE 2 and APOE 24 and 671 GRS^{APOE} includes only the SNPs rs7412 and rs429358. The formula used to calculate the 672 different GRSs is as follow: 673

$GRS_{sample} = \sum_{i=1}^{83} (\beta_i * dosage_{i_sample}) * Nvariants / \sum \beta$

674

Where dosage_i is the risk allele dosage or genotype of variant_i β_i is extracted from stage II 675 meta-analysis summary statistics (including the ADGC, CHARGE and FinnGen data), at the 676 exception of APOE variants, where the β_i are extracted from the summary statistics of the 677 678 last UK Biobank's GWAS (unpublished data). The last multiplication term is the number of 679 variants divided by the sum of βs . Thanks to this term, one unit of this transformed GRS corresponds to one additional risk allele³³. 680

681

Sample and variant Quality controls 682

To have a complete independence of the β s extracted from summary statistics, all samples 683 from ADGC, CHARGE and FinnGen GWASes were filtered out. After meeting the classical 684 GWAS gold standard of sample quality control, each sample was included in the analyses³⁴. 685 If a variant dose, covariate, or discordance between imputed and genotyped (if available) 686 APOE status was observed, the sample was discarded. After QC, a demographic description 687 of each study is shown in Supplementary Table 1. 688

In case of genotyping data, if the variants are genotyped, they should meet the gold standard 689 of GWAS variant QC³⁴. All the studies were also imputed with the TOPmed reference 690 panel^{35,36}, at the exception of the Korean one, which was imputed with the Haplotype 691 Reference Consortium imputation panel³⁷. If the variants were imputed, variants with a Rsq 692 bellow 0.3 were excluded. In case of WGS data, only variants passing the WGS QC are kept 693 694 (see supplementary information for ADSP and China sample)(Supplementary Table 2). The global ancestry of each individual in ADSP and MVP was determined with SNPweights 695 v.2.1³⁸ (see supplementary information). 696

697

European mega-analysis methods 698

699 For the mega-analysis of European countries, we merged samples from 5 datasets : EADBcore, GERAD, EADI, Demgene and Bonn. To adjust for population structure, we computed 700 principal components using the following procedure. From the 146,705 variants used in the 701 principal component analysis of EADB-core³⁹, we extracted from this list, TOPMed imputed 702 variants having an imputation quality ≥ 0.9 in each dataset, resulting in 91,353 variants. Then, 703 we put any genotype to missing if none of the genotype probabilities was higher than 0.8. 704 Finally, we merged all datasets and removed variants having a proportion of missing 705 genotypes higher than 0.02 leading to 90,471 variants used for the principal component 706 707 analysis. This analysis was performed by flashPCA2. Analyses were adjusted for the 14 firsts 708 principal components, the genotyping chip and center.

709

Statistical analyses 710

The association of AD status with the GRSs was tested with different models, named 711

according to the GRS and covariates included in the logistic regression (see supplementary 712 713 Table 1 for covariates).

Model GRS^{ALZ}: AD ~ GRS^{ALZ} + COV 714

Model GRS^{ALZadjAPOE}: AD ~ GRS^{ALZ} + COV + number of APOE ε^2 alleles + number of 715 716 APOE ε4 alleles

- Model GRS^{ALZincIAPOE}: AD ~ GRS^{ALZincIAPOE} + COV 717 -
- Model GRS^{APOE}: AD ~ GRS^{APOE} + COV 718
- 719 720

Quantile or Percentile analyses

Depending on the value of their GRS, the samples were divided into the reference group or 721 one of the test groups. In the mega-analysis, the reference group corresponded to the 40-722 723 60% percentile and was tested across each percentile (0-2%, 2-5%, 5-10%, 10-20%, 20-40%, 60-80%, 80-90%, 95-98%, 98-100%). In the APOE stratified analysis, the reference 724 group was defined by the 40-60% percentile and was tested across quantile (0-20%, 20-725 40%, 60-80%, 80-100%). In the multi-ancestry analyses, the reference group was defined by 726 the 40-60% percentile and was also tested across quantile (0-20%, 20-40%, 60-80%, 80-727 100%). These analyses were performed by population and then meta-analyzed per ancestry, 728 using the inverse variance method, implemented in METAL⁴⁰. To note, Indian, North-Africa 729 and sub-Saharan Africa populations were excluded because of their small sample size. 730

- 731 Model GRS^{ALZ}: AD ~ Group_{0/1}(GRS^{ALZ}) + COV _
- Model GRS^{ALZadjAPOE}: AD ~ Group_{0/1}(GRS^{ALZ}) + COV + number of APOE ϵ 2 alleles + 732 number of APOE ε4 alleles 733
- Model GRS^{ALZinclAPOE}: AD ~ Group_{0/1}(GRS^{ALZinclAPOE}) + COV 734 _

735 References 736

737 738

741

742

746

747

748

749

750

- 33. Chouraki, V. et al. Evaluation of a genetic risk score to improve risk prediction for Alzheimer's disease. J. Alzheimers Dis. 53, 921-932 (2016).
- 34. Bellenguez, C. et al, New insights into the genetic etiology of Alzheimer's disease and related 739 740 dementias. Nat. Genet. 54, 412-436 (2022
 - 35. Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature 590, 290-299 (2021).
- 36. Das, S. et al. Next-generation genotype imputation service and methods. Nat. Genet. 48, 743 744 1284-1287 (2016). 745
 - 37. McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat. Genet. 48, 1279-1283 (2016).
 - 38. Chen, C.Y. et al. Improved ancestry inference using weights from external reference panels. Bioinformatics 2, 1399-406 (2013).
 - 39. Abraham, G. et al. FlashPCA2: principal component analysis of Biobank-scale genotype datasets. Bioinformatics 33, 2776-2778 (2017).
- 40. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide 751 752 association scans. Bioinformatics 26, 2190-1 (2010).

753 754 Data Availability

- ADSP: https://dss.niagads.org/datasets/ng00067/ 755
- 756

Code availability 757

- 758 Code are available upon requests
- 759
- 760 761
- 762
- 763
- 764

medRxiv preprint doi: https://doi.org/10.1101/2023.10.17.23297061; this version posted October 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

Table 1. Association of GRS^{ALZadjAPOE} with AD, AD and related dementia (ADRD) and 765 dementia in MVP. 766

Ancostry	Disease Ncases	Ncontrols –	GRS ^{ALZadjAPOE}			
Ancestry	Disease	NCdSes	NCONTOIS -	OR	95% CI	P-value
	AD	4,561		1.10	1.09-1.11	1.73x10 ⁻⁸⁸
European American	ADRD	17,519	84,587	1.06	1.06-1.07	1.94x10 ⁻¹¹¹
	Dementia	26,473		1.05	1.04-1.05	5.82x10 ⁻⁸³
US LA Ancestry	AD	375	7,166	1.07	1.04-1.11	1.47x10 ⁻⁵
	ADRD	1,527		1.02	1.00-1.04	1.27x10 ⁻²
	Dementia	1,981		1.02	1.00-1.03	2.22x10 ⁻²
	AD	713		1.05	1.03-1.08	5.38x10 ⁻⁶
African American	ADRD	4,016	19,405	1.02	1.01-1.02	9.29x10 ⁻⁴
	Dementia	4,702		1.02	1.01-1.03	8.84x10 ⁻⁴

767 768

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Figure 1: Association of (A) GRS^{alz} and (B) GRS^{ALZadjAPOE} with the risk of developing AD

in 15 European countries. Ncase, number of cases; Ncontrols, number of controls; OR, 770 Odds ratio. The lines in the Forrest plots indicate the 95% confidence interval for the ORs. 771 772 773 Figure 2: Relation between the different GRSs and APOE status on the risk of developing AD. (A) Risk of developing AD according to GRS strata (0-2%, 2-5%, 10-20%, 774 20-40%, 60-80%, 80-90%, 90-95%, 95-98%, 98-100%) for GRS^{ALZ}, GRS^{ALZadjAPOE} and 775 GRZ^{ALZIncIAPOE}. The 40-60% GRS stratum was used as the reference; **(B)** Risk of developing 776 AD according to GRS^{ALZ} strata (0-20%, 20-40%, 60-80% and 80-100%) and to the APOE 777 778 genotype by grouping together the $\varepsilon 2\varepsilon 2/\varepsilon 2\varepsilon 3$, $\varepsilon 3\varepsilon 3$, $\varepsilon 2\varepsilon 4/\varepsilon 3\varepsilon 4$, $\varepsilon 4\varepsilon 4$ carriers. The 40-60% GRS stratum was used as the reference. 779

780

769

Figure 3: Association of (A) GRS^{alz} and (B) GRS^{ALZadjAPOE} with the level of A β 42, Tau 781 and p-TAU in the cerebrospinal fluid in European-ancestry populations. Ncase, number 782 783 of cases; Ncontrols, number of controls, OR, Odds ratio. The lines in the Forrest plots 784 indicate the 95% confidence interval for the ORs. 785

Figure 4: World map showing the populations analysed. A colour gradient indicates the 786 787 magnitude of the association of APOE $\epsilon 2/\epsilon 3/\epsilon 4$ alleles with the risk of developing AD in 788 different countries (all values are shown in Supplementary Table 5).


789 Figure 5: Association of (A) GRS^{alz} and (B) GRS^{ALZadjAPOE} with the risk of developing AD 790 791 in multi-ancestry populations. Ncase, number of cases; Ncontrols, number of controls; OR, 792 Odds ratio. The lines in the Forrest plots indicate the 95% confidence interval for the ORs. 793 African-American-ancestry (more than 75% AA ancestry) meta-analysis includes MVP and 794 ADSP. East-Asia meta-analysis includes China, Korea and Japan. Latino-American ancestry 795 (self-reporting) meta-analysis includes MMVP, ADSP and Salsa. South-America meta-796 analysis includes Argentina, Brazil, Chile and Colombia. 797

Figure 6: Risk of developing AD according to GRS (GRS^{ALZ}, GRS^{ALZadjAPOE} and 798 GRZ^{ALZIncIAPOE}) strata (0-20%, 20-40%, 60-80% and 80-100%) in multi-ancestry 799 800 populations. Ncase, number of cases; Ncontrols, number of controls; OR, Odds ratio. The lines in the Forrest plots indicate the 95% confidence interval for the ORs. The 40-60% GRS 801 stratum was used as the reference in each population and results were meta-analyzed. 802 803 African-American ancestry meta-analysis includes MVP and ADSP. East-Asia meta-analysis includes China, Korea and Japan. Latina-American ancestry meta-analysis includes MVP 804 805 and ADSP. South-America meta-analysis includes Argentina, Brazil, Chile and Colombia.

GRS^{ALZ} I² = 3.9 , HetP = 4.08e-01

Figure 1 A


Country	Ncases	Ncontrols	OR	95% CI	P-value		
medRxiv p Finland preprint				23297061; this versio au[hor()@nder1/v4h]o			
Norway	1,327	1 lt 1s719 ad	e avail a bl e 3 nd	berpetuity. ler a CO-0 Y1NC5]0	Integn@lpeal2opnse	•	
Sweden	1,466	3,078	1.14	[1.12;1.16]	1.60e-42		
Denmark	398	650	1.13	[1.09;1.18]	5.29e-10		
United Kingdor	n 4,622	8,414	1.13	[1.11;1.14]	8.78e-85		
The Netherland	ls 2,428	2,024	1.11	[1.09;1.13]	3.80e-28		
Belgium	1,211	1,431	1.13	[1.10;1.16]	1.58e-18		
Germany	2,190	3,141	1.12	[1.10;1.14]	5.71e-43		
Switzerland	175	372	1.07	[1.01;1.12]	1.66e-02		
Czech Republi	c 177	60	1.12	[1.02;1.25]	1.97e-02		
Bulgaria/Greec	e 735	1,195	1.10	[1.05;1.14]	1.44e-05		
France	3,789	9,026	1.12	[1.11;1.13]	3.19e-85		
Italy	2,973	1,251	1.13	[1.10;1.15]	2.52e-31		
Spain	3,103	1,615	1.14	[1.12;1.16]	1.48e-41		
Portugal	80	74	1.08	[0.98;1.18]	1.14e-01		
Meta-analysis	25,792	35,280	1.12	[1.12;1.13]	1.07e-412		
						0.95	1.00





В


 $GRS^{ALZadjAPOE}$ $I^2 = 9.2$, HetP = 3.50e-01

Country	Ncases	Ncontrols	OR	95% CI	P-value
Finland	1,118	1,770	1.10	[1.08;1.13]	2.32e-14
Norway	1,327	1,179	1.13	[1.10;1.16]	8.43e-20
Sweden	1,466	3,078	1.14	[1.12;1.17]	2.27e-37
Denmark	398	650	1.13	[1.08;1.17]	2.08e-08
United Kingdom	4,622	8,414	1.12	[1.11;1.14]	3.13e-73
The Netherlands	2,428	2,024	1.10	[1.08;1.13]	6.50e-24
Belgium	1,211	1,431	1.13	[1.10;1.16]	2.20e-17
Germany	2,190	3,141	1.12	[1.10;1.14]	9.18e-37
Switzerland	175	372	1.06	[1.01;1.12]	2.32e-02
Czech Republic	177	60	1.14	[1.03;1.27]	1.81e-02
Bulgaria/Greece	735	1,195	1.10	[1.05;1.15]	1.52e-05
France	3,789	9,026	1.11	[1.10;1.13]	4.69e-73
Italy	2,973	1,251	1.12	[1.10;1.15]	2.15e-27
Spain	3,103	1,615	1.14	[1.11;1.16]	2.91e-36
Portugal	80	74	1.07	[0.98;1.18]	1.42e-01
Meta-analysis	25,792	35,280	1.12	[1.11;1.13]	2.20e-353










medRxiv preprint doi: https://doi.org/10.1101/2023.10.17.23297061; this version posted October 19, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .


С			l ²	Tau (GRS ^{AL} = 0 , HetP = 5.2	.Z) 7e-0
Study	Ν	Beta	95% CI	P-value	
Finland	226	0.027	[-0.02;0.08]	3.05e-01	
Sweden	264	0.039	[0.01;0.07]	1.17e-02	
The Netherlands	3,106	0.036	[0.03;0.04]	1.90e-15	
Germany 1	314	0.026	[-0.00;0.06]	7.95e-02	
Germany 2	155	0.002	[-0.05;0.05]	9.54e-01	
Germany 3	145	0.020	[-0.03;0.07]	3.97e-01	
Germany 4	112	-0.026	[-0.07;0.02]	2.82e-01	
Belgium	598	0.030	[0.01;0.05]	5.51e-03	
France 1	439	0.030	[0.00;0.06]	2.54e-02	
France 2	135	0.027	[-0.01;0.07]	2.07e-01	
Spain	408	0.041	[0.01;0.07]	2.16e-03	
Meta-analysis Adjusted for status	5,902 S	0.032	[0.03;0.04]	1.29e-21 6.35e-08	




0.05

D

Study	Ν	Beta	95% CI	P-value
Finland	226	0.021	[-0.03;0.07]	4.01e-01
Sweden	264	0.029	[-0.00;0.06]	5.31e-02
The Netherlands	3,106	0.032	[0.02;0.04]	5.43e-13
Germany 1	314	0.015	[-0.01;0.04]	2.90e-01
Germany 2	155	0.001	[-0.05;0.05]	9.66e-01
Germany 3	145	0.026	[-0.02;0.07]	2.71e-01
Germany 4	112	-0.025	[-0.07;0.02]	3.05e-01
Belgium	598	0.029	[0.01;0.05]	5.70e-03
France 1	439	0.023	[-0.00;0.05]	6.72e-02
France 2	135	0.028	[-0.01;0.07]	1.87e-01
Spain	408	0.032	[0.01;0.06]	1.27e-02
Meta-analysis	5,902	0.028	[0.02;0.03]	2.23e-17
Adjusted for statu	IS			3.36e-07







F

Study	Ν	Beta	95% CI	P-value
Finland	226	0.025	[-0.03;0.08]	3.56e-01
Sweden	264	0.027	[-0.00;0.06]	8.14e-02
The Netherlands	3,106	0.028	[0.02;0.04]	4.22e-10
Germany 1	314	0.005	[-0.02;0.03]	7.55e-01
Germany 2	155	-0.007	[-0.06;0.05]	7.94e-01
Germany 3	145	0.013	[-0.03;0.06]	5.64e-01
Germany 4	112	-0.012	[-0.06;0.04]	6.44e-01
Belgium	598	0.022	[0.00;0.04]	3.54e-02
France 1	439	0.022	[-0.00;0.05]	7.84e-02
France 2	135	0.014	[-0.03;0.06]	5.38e-01
Spain	408	0.023	[-0.00;0.05]	8.77e-02
Meta-analysis	5,902	0.024	[0.02;0.03]	2.83e-12
Adjusted for statu	IS			6.99e-05

		AB ₄	
		$I^2 =$	66.6 , HetP
Ν	Beta	95% CI	P-value
226	-0.046	[-0.08;-0.01]	1.22e-02
264	-0.017	[-0.05;0.01]	2.52e-01
3,106	-0.032	[-0.04;-0.02]	1.22e-14
314	-0.012	[-0.04;0.02]	3.99e-01
155	0.006	[-0.04;0.05]	8.21e-01
145	-0.054	[-0.09;-0.01]	1.04e-02
112	0.025	[-0.02;0.07]	3.23e-01
598	0.006	[-0.01;0.03]	5.59e-01
439	-0.008	[-0.03;0.01]	4.87e-01
135	0.016	[-0.02;0.06]	4.34e-01
408	-0.040	[-0.06;-0.02]	7.04e-04
5,902	-0.024	[-0.03;-0.02]	1.21e-14
IS			2.74e-06
	226 264 3,106 314 155 145 145 112 598 439 135 408 5,902	226 -0.046 264 -0.017 3,106 -0.032 314 -0.012 155 0.006 145 -0.054 112 0.025 598 0.006 439 -0.008 135 0.016 408 -0.040	$I^{2} = N \qquad Beta \qquad 95\% CI$ $226 \qquad -0.046 \qquad [-0.08;-0.01]$ $264 \qquad -0.017 \qquad [-0.05;0.01]$ $3,106 \qquad -0.032 \qquad [-0.04;-0.02]$ $314 \qquad -0.012 \qquad [-0.04;0.02]$ $155 \qquad 0.006 \qquad [-0.04;0.05]$ $145 \qquad -0.054 \qquad [-0.09;-0.01]$ $112 \qquad 0.025 \qquad [-0.02;0.07]$ $598 \qquad 0.006 \qquad [-0.01;0.03]$ $439 \qquad -0.008 \qquad [-0.03;0.01]$ $135 \qquad 0.016 \qquad [-0.02;0.06]$ $408 \qquad -0.040 \qquad [-0.06;-0.02]$







 $I^2 = 0$, HetP = 6.72e-01




Figure 4






Figure 5 A

Country	Ncases	Ncontrols	OR	95% CI	P-value
European American MVP	4,561	84,587	1.10	[1.09;1.11]	2.40e-81
Maghreb	58	187	1.11	[1.00;1.24]	4.81e-02
Sub-Saharan Africa	87	1,113	1.02	[0.98;1.07]	3.07e-01
African American MVP	713	19,405	1.05	[1.02;1.07]	5.12e-05
African American ADSP	1,152	2,451	1.04	[1.02;1.06]	3.75e-05
Meta-analysis AA Ancestry	1,865	21,856	1.04	[1.03;1.06]	8.60e-09
US LA Ancestry MVP	375	7,166	1.07	[1.04;1.11]	3.38e-05
US LA Ancestry SALSA	79	657	1.03	[0.97;1.10]	3.36e-01
US LA Ancestry ADSP	1,780	2,489	1.06	[1.04;1.07]	6.26e-12
Colombia	254	241	1.07	[1.01;1.12]	1.45e-02
Brazil	301	176	1.11	[1.06;1.16]	1.39e-05
Argentina	417	601	1.08	[1.04;1.12]	1.51e-04
Chile	122	252	1.16	[1.09;1.24]	5.60e-06
Meta-analysis US LA Ancestry	2,234	10,312	1.06	[1.04;1.07]	1.04e-15
Meta-analysis South America	1,094	1,270	1.09	[1.07;1.12]	1.47e-13
Meta-analysis LA Ancestry	3,328	11,582	1.07	[1.05;1.08]	1.43e-26
China	453	786	1.10	[1.05;1.14]	2.33e-06
JapanedRxiv preprint doi: https://doi.org/10.110 preprint (which was not certified by pee South Korea	01/2023,7056.	23297061;, Me Sers	sion posted Oc o has granted	tobel 19,52023. He a medRxiv_a license to	copyrlon Roller for this display the preprint in
Meta-analysis East Asia	de available un 3,328	der a CC-BY-NC 4. 3,823	.0 Internationa 1 08	[1.07;1.10]	1.05e-29
	,	,			
India	110	1,548	1.00	[0.95;1.05]	9.37e-01




В

Country	Ncases	Ncontrols	OR	95% CI	P-value
European American MVP	4,561	84,587	1.10	[1.09;1.11]	1.73e-88
Maghreb	58	187	1.10	[0.99;1.23]	9.15e-02
Sub-Saharan Africa	87	1,113	1.02	[0.98;1.07]	3.38e-01
African American MVP	713	19,405	1.05	[1.03;1.08]	5.38e-06
African American ADSP	1,152	2,451	1.03	[1.01;1.05]	4.25e-04
Meta-analysis AA Ancestry	1,865	21,856	1.04	[1.03;1.06]	1.86e-08
US LA Ancestry MVP	375	7,166	1.07	[1.04;1.11]	1.47e-05
US LA Ancestry SALSA	79	657	1.03	[0.97;1.10]	3.62e-01
US LA Ancestry ADSP	1,780	2,489	1.06	[1.04;1.08]	5.14e-12
Colombia	254	241	1.06	[1.00;1.11]	4.31e-02
Brazil	301	176	1.11	[1.06;1.17]	7.09e-06
Argentina	417	601	1.08	[1.03;1.12]	2.54e-04
Chile	122	252	1.15	[1.08;1.23]	5.96e-05
Meta-analysis US LA Ancestry	2,234	10,312	1.06	[1.05;1.08]	4.75e-16
Meta-analysis South America	1,094	1,270	1.09	[1.06;1.12]	2.87e-12
Meta-analysis LA Ancestry	3,328	11,582	1.07	[1.06;1.08]	5.84e-26
China	453	786	1.09	[1.05;1.14]	1.12e-05
Japan	1,756	1,865	1.09	[1.06;1.11]	9.80e-13
South Korea	1,119	1,172	1.07	[1.05;1.09]	1.47e-10
Meta-analysis East Asia	3,328	3,823	1.08	[1.06;1.10]	1.01e-25
-		·			
India	110	1,548	1.00	[0.95;1.05]	9.02e-01



GRS^{ALZ}

GRS^{ALZadjAPOE}



Β

GRSALZinclAPOE

